Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2000
|
| gptkbp:ATCCode |
gptkb:A10BX03
|
| gptkbp:CASNumber |
gptkb:105816-04-4
|
| gptkbp:chemicalFormula |
C19H27NO3
|
| gptkbp:contraindication |
gptkb:diabetic_ketoacidosis
type 1 diabetes |
| gptkbp:drugClass |
biguanide
|
| gptkbp:eliminationHalfLife |
1.5 hours
|
| gptkbp:genericName |
gptkb:nateglinide
|
| https://www.w3.org/2000/01/rdf-schema#label |
Starlix
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Novartis
|
| gptkbp:mechanismOfAction |
stimulates insulin secretion
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:hypoglycemia
back pain upper respiratory tract infection |
| gptkbp:status |
approved
|
| gptkbp:usedFor |
gptkb:type_2_diabetes
|
| gptkbp:bfsParent |
gptkb:Novartis
|
| gptkbp:bfsLayer |
4
|